TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
TQB2223 is a recombinant, fully humanized antibody that binds lymphocyte activation gene-3
(LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction,
thus allowing for increased T-cell proliferation and cytokine production. This is a phase I
study to evaluate the safety, tolerability, pharmacokinetics (PK) and effectiveness of
TQB2223 injection in combination with Penpulimab in subjects with advanced cancers.